While the current focus of development for menin inhibitors is in AML, bleximinib (JNJ-75276617), enzomenib, and ziftomenib are also under investigation in ALL with KMT2A rearrangements [143,163,166,167,168]. Here, MEN1 is linked to acute lymphoblastic leukemia.